Close Menu

NEW YORK – Adaptive Biotechnologies and Microsoft are expanding their existing partnership on mapping adaptive immune responses population-wide to include COVID-19, the companies said on Friday.

Beginning in April, Adaptive will collect de-identified blood samples from patients diagnosed with or recovered from COVID-19. It will sequence the samples and map the immune cell receptor profiles to antigens from SARS-CoV-2, the virus that causes COVID-19. The partners will then upload the immune response signatures to an open-access data portal.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

Sponsored by

This webinar features two speakers who will discuss novel computational approaches to optimize sequencing workflows on Oxford Nanopore sequencing platforms.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.